dexamethasone dose as an adjuvant in supra clavicular block

Lower effective dose of dexamethasone as an adjuvant to bupivacaine in supra-clavicular block: comparetive study.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202003487312437

Enrollment

Registered

2020-03-17

Start date

2020-03-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia

Interventions

bupivacine only

bupivacine and 3 mg dexamethasone

bupivacine and 4 mg dexamethasone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: adults of both sex ASA I or II aging 18-65 years undergoing upper limb orthopedic surgery in mansoura university hospitals.

Exclusion criteria

Exclusion criteria: • patient refusal • allergy to local anesthetics • infection at injection site • malignancy at the needle entry site • coagulopathy • patients maintained on anticoagulation therapy • severe pulmonary disease • preexisting neural deficits exist in the distribution of the block.

Design outcomes

Primary

Measure	Time frame
analgesia duration	—

Secondary

Measure	Time frame
total dose pethidine consumption 24 h, post operative;heart rate, MABP, respiratory rate, Spo2, RBS;complication like infection , delayed wound healing	—

Countries

Egypt

Contacts

Public Contactsamah elkenany

assistant proffesor of anaesthesia mansoua university

sk_20022000@yahoo.com00201002262557

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026